 Biocept Inc NASDAQ:BIOC told investors it was continuing to position itself as a leader in neurological tumor diagnostics as the company released second-quarter results, which included the first revenue from a biopharma firm using its CNSide in a clinical trial. Biocepts CNSide cerebrospinal fluid assay can detect cancer cells that have metastasized to the central nervous system. 